Audits - Obstetrics, Gynaecology & Urinary Tract Disorders

Please select from the following Audits.

Review of antimuscarinics in urinary frequency, urgency and urge incontinence

Patients who suffer from detrusor muscle over-activity and urge incontinence may benefit from anti-muscarinic therapy in addition to pelvic floor exercises, bladder retraining and lifestyle interventions. Previous SIGN guidance in this therapeutic area (SIGN 79) was withdrawn in 2015 which means that the most recent UK based national clinical guideline is NICE CG171 (first published in 2013 and updated in 2015). This guideline recommends that antimuscarinic therapy be reviewed four weeks following its commencement to assess the extent of any therapeutic benefit and the degree of any adverse effects. Medication should be continued where a satisfactory therapeutic response has been achieved whilst in those instances where adverse effects have proved to be problematic, an alternative antimuscarinic should be tried. In the event of treatment being continued, review of ongoing need should take place annually in those aged under 75 years and every 6 months in those aged over 75 years.

Review of antimuscarinics in urinary frequency, urgency and urge incontinenceDownload File
(Antimuscarinics in urinary freq updated July 17.pdf)

Date Uploaded: 06/07/2017

Home / Audits

Urinary Drainage Bag Audit

Across D&G in 2006/07, 93,200 and 41,300 was spent on leg and night drainage bags respectively. Large quantities of leg and night bags were disposed of during the region-wide medicines waste campaign in 2007 suggesting over-ordering/over-prescribing and potential educational needs for patients and healthcare professionals. This audit aims to identify patients for review who Over-order supplies Under-order supplies Have inappropriately low or high quantities available per prescription Receive catheter supplies but were not previously known to the regional continence team

Urinary Drainage Bag AuditDownload File
(Urinary Drainage Bags AuditProtocolOct08.pdf)

Date Uploaded: 08/10/2008

Home / Audits

Tamsulosin Audit

Tamsulosin is the first subtype-selective (alpha IA) alpha 1 adrenoceptor antagonist with specificity for prostatic alpha 1 adrenoceptors (alpha 1A adrenoceptors are thought to be involved in prostatic smooth muscle contraction) to become available for the treatment of patients with symptomatic benign prostatic hyperplasia (BPH)

Alpha 1 blockade acts to relax prostatic smooth muscle producing an increase in urinary flow rate and an improvement in obstructive symptoms



Tamsulosin AuditDownload File
(Microsoft Word - Tamsulosin Audit April 2008.pdf)

Date Uploaded: 11/04/2008

Home / Audits

Home | About | Glossary | Web Links | Local Links | Site Map | Disclaimer | Contact

© Primary Care Development | Crichton Hall | Bankend Road | Dumfries | Dumfries & Galloway | Scotland | DG1 4TG

Valid CSS!Valid HTML 4.01 Transitional

Website design, hosting and maintenance by:
NJ Web Design